Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study
Authors' conclusion
DEX-based sedation compared to propofol/midazolam-based sedation did not show any significant difference in S100-β or any other markers of SE in critically ill patients with sepsis requiring mechanical ventilation.
Study context
- Population
- Adults with sepsis admitted to the ICU requiring intubation and ongoing sedation, single-centre University Hospital, Switzerland, 2019–2022
- Participants
- 70 adults
- Comparison
- Dexmedetomidine (DEX)-based vs propofol and/or midazolam-based sedation
- DEXn = 34
- Propofol/midazolamn = 36reference
Methodological detailspilot, open-label, single-centre
- Pilot
- Open-label
- Single-centre
Primary result
As reported in the abstract
Serum S100-β · 48 hr
DEX
0.103
median · IQR 0.052–0.194 · ng/ml
Propofol/midazolam
0.189
median · IQR 0.086–0.368 · ng/mL
P = 0.064
Further findings
Serum S100-β, GCS ≤13 (subgroup)
P = 0.033
Other biomarkers
- No differences over time
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study. Crit Care Med. Published 31 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →